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Selective regulation of IP3-receptor-mediated
Ca2þ signaling and apoptosis by the BH4 domain
of Bcl-2 versus Bcl-Xl
G Monaco1,5, E Decrock2,5, H Akl1, R Ponsaerts1, T Vervliet1, T Luyten1, M De Maeyer3, L Missiaen1, CW Distelhorst4, H De Smedt1,
JB Parys1, L Leybaert2 and G Bultynck*,1
Antiapoptotic B-cell lymphoma 2 (Bcl-2) targets the inositol 1,4,5-trisphosphate receptor (IP3R) via its BH4 domain, thereby
suppressing IP3R Ca
2þ -flux properties and protecting against Ca2þ -dependent apoptosis. Here, we directly compared IP3R
inhibition by BH4-Bcl-2 and BH4-Bcl-Xl. In contrast to BH4-Bcl-2, BH4-Bcl-Xl neither bound the modulatory domain of IP3R nor
inhibited IP3-induced Ca
2þ release (IICR) in permeabilized and intact cells. We identified a critical residue in BH4-Bcl-2 (Lys17)
not conserved in BH4-Bcl-Xl (Asp11). Changing Lys17 into Asp in BH4-Bcl-2 completely abolished its IP3R-binding and
-inhibitory properties, whereas changing Asp11 into Lys in BH4-Bcl-Xl induced IP3R binding and inhibition. This difference in
IP3R regulation between BH4-Bcl-2 and BH4-Bcl-Xl controls their antiapoptotic action. Although both BH4-Bcl-2 and BH4-Bcl-Xl
had antiapoptotic activity, BH4-Bcl-2 was more potent than BH4-Bcl-Xl. The effect of BH4-Bcl-2, but not of BH4-Bcl-Xl, depended
on its binding to IP3Rs. In agreement with the IP3R-binding properties, the antiapoptotic activity of BH4-Bcl-2 and BH4-Bcl-Xl was
modulated by the Lys/Asp substitutions. Changing Lys17 into Asp in full-length Bcl-2 significantly decreased its binding to the
IP3R, its ability to inhibit IICR and its protection against apoptotic stimuli. A single amino-acid difference between BH4-Bcl-2 and
BH4-Bcl-Xl therefore underlies differential regulation of IP3Rs and Ca
2þ -driven apoptosis by these functional domains. Mutating
this residue affects the function of Bcl-2 in Ca2þ signaling and apoptosis.
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Pro- and anti-apoptotic B-cell lymphoma 2 (Bcl-2) family
members control cell survival by regulating programmed cell
death and autophagy.1 The founding member is Bcl-2, a 26-
kDa protein localized in the mitochondrial and endoplasmic-
reticulum (ER) membranes. Members of this protein family
are characterized by the presence of Bcl-2 homology domains
(BH domains).2,3 Although multidomain proapoptotic proteins
contain three BH domains (BH1, BH2 and BH3),
the antiapoptotic proteins, like Bcl-2 and Bcl-Xl, are char-
acterized by an additional BH domain (BH4).1 The BH1,
BH3 and BH2 domains of the antiapoptotic Bcl-2 family
proteins form a hydrophobic pocket that binds the BH3
domain of proapoptotic proteins, thereby counteracting
their proapoptotic activity.4 Besides this hydrophobic cleft,
the BH4 domain is also essential for the antiapoptotic activity
of Bcl-2.5,6
Moreover, Ca2þ signaling from the ER to the mitochondria
plays an important role in apoptosis initiation.7 Several
pro- and anti-apoptotic Bcl-2 proteins localize at the ER
membrane, where they modulate Ca2þ -release events8,9
(recently reviewed in Rong et al.10 and Rizzuto et al.11). Bcl-2
proteins thereby influence mitochondrial function because of
the close proximity of ER and mitochondrial membranes.12–14
Ca2þ transfer via the ER–mitochondria connection plays a
bimodal role in cell survival.15,16 Small oscillatory Ca2þ
signals promote survival by stimulating mitochondrial function
and bioenergetics, whereas larger mitochondrial [Ca2þ ] rises
promote cell death by provoking mitochondrial outer
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membrane permeabilization (MOMP).11,13,14,17,18 Thus, both
promoting cytosolic Ca2þ oscillations and blunting cytosolic
Ca2þ transients underpin the antiapoptotic action of Bcl-2
family members.19
Different studies demonstrated that inositol 1,4,5-trispho-
sphate receptors (IP3Rs) play a central role in this paradigm
as targets of Bcl-2, Bcl-Xl and Mcl-1.20–25 However, the
localization of their interaction sites on the IP3R as well as the
physiological roles of these interactions remain unsolved.
Different, not mutually exclusive, mechanisms have been
proposed. (1) Increasing the ratio of anti- over pro-apoptotic
Bcl-2 proteins caused IP3R sensitization, enhancing basal
IP3R-mediated Ca
2þ leak and reducing steady-state [Ca2þ ]
in the ER.20 (2) Bcl-Xl interacted with the C-terminus of IP3Rs,
promoting spontaneous Ca2þ oscillations and enhancing
mitochondrial bioenergetics.23,26 (3) Bcl-2 directly inhibited
IP3Rs without altering steady-state ER Ca
2þ levels.21,22,27
Recently, the Bcl-2 interaction domain was identified in the
central, modulatory region of the IP3R (amino acids (a.a.)
1389–1408).28 Disturbing endogenous IP3R/Bcl-2 complexes
potentiated IP3-induced Ca
2þ release (IICR) and sensitized
cells toward proapoptotic Ca2þ signaling.28 The BH4 domain
of Bcl-2 was necessary and sufficient for interaction with the
IP3R.
29,30 (4) Bcl-Xl reduced the expression levels of IP3Rs
via a decreased binding of NFATc2 (nuclear factor of
activated T cells, cytoplasmic, calcineurin-dependent 2) to
the IP3R promoter,
31 thereby reducing IICR.
Here, we directly compared the regulation of IP3Rs by the
BH4 domains of Bcl-2 and Bcl-Xl. Our results indicate that
although the BH4 domain of Bcl-2 and Bcl-Xl are very similar
in sequence and structure, a difference in one single residue
between BH4-Bcl-2 and BH4-Bcl-Xl critically determined its
IP3R binding, suppression of IP3R activity and protection
against IP3R-driven apoptosis.
Results
BH4-Bcl-2 and BH4-Bcl-Xl differentially regulate
IICR. The structure of antiapoptotic Bcl-2 and of a
monomeric subunit of the IP3R1 is depicted in Figure 1a,
including the interaction of Bcl-2 via its BH4 domain with the
IP3R1. The IP3R-derived peptide (IDP; a.a. 1389–1408)
corresponds to the Bcl-2-binding site on IP3R1 and is
therefore able to disrupt Bcl-2/IP3R interaction in a
competitive way. IDP completely alleviates the inhibitory
action of the BH4 domain of Bcl-2 on IP3Rs without affecting
other BH4-domain targets, like voltage-dependent anion
channel (VDAC) and calcineurin.29 Thus, IDP is an
excellent tool to decipher the role of IP3R in the observed
actions of BH4-Bcl-2 on intracellular Ca2þ signaling and cell
death. Here, we directly compared the effect of BH4-Bcl-2
and BH4-Bcl-Xl on IICR using a unidirectional 45Ca2þ -flux
assay in saponin-permeabilized mouse embryonic fibroblasts
(MEF cells) in which the non-mitochondrial Ca2þ stores were
loaded to steady state with 45Ca2þ . After adding 4 mM
thapsigargin (TG), the efflux of 45Ca2þ was followed in the
presence of 1mM ethylene glycol tetraacetic acid (EGTA).
This assay allows the quantitative assessment of Ca2þ -
efflux properties under unidirectional conditions in the
absence of ER and mitochondrial Ca2þ -uptake activity.
Ca2þ content (Figure 1b) and fractional loss (Figure 1c) were
plotted as a function of time. Figure 1b shows that because of
an inherent Ca2þ leak, the Ca2þ content of the stores slowly
decreased over time, whereas adding IP3 (3 mM) accelerated
the decrease in Ca2þ content due to IICR, observed as a
steep increase in the fractional loss (Figure 1c). The BH4
domains of Bcl-2 (BH4-Bcl-2; a.a. 6–30) and Bcl-Xl (BH4-
Bcl-Xl; a.a. 1–24) were produced as synthetic peptides. A
scrambled version of the BH4 domain of Bcl-2 (BH4-Bcl-
2SCR) and a ‘binding-deficient’ version of BH4-Bcl-2, in
which the surface-accessible residues were altered
(BH4-Bcl-2BIND),30 were used as negative controls. The
45Ca2þ -flux assays showed that BH4-Bcl-2 caused a potent
concentration-dependent inhibition of IICR (Figures 1b and c).
Importantly, BH4-Bcl-2 did not alter the Ca2þ -leak rate from
the ER in the absence of IP3. In contrast to BH4-Bcl-2, BH4-
Bcl-2BIND and BH4-Bcl-2SCR did not inhibit IICR (Figure 1d
and Supplementary Figures 1A and B). BH4-Bcl-2 inhibited
IICR with a half-maximal inhibitory concentration (IC50) of
B30 mM and an IC100 of B100mM (Figure 1d). Strikingly,
BH4-Bcl-Xl did not inhibit IICR (estimated IC50 4500mM)
Figure 1 Although the BH4 domains of Bcl-2 and Bcl-Xl are similar in sequence and structure, they differentially regulate IP3R-mediated Ca
2þ flux in permeabilized and
intact cells. (a) Schematic presentation of the antiapoptotic Bcl-2-family members and the IP3R. The N-terminal BH4 domain is unique for antiapoptotic members. The
secondary structure and primary sequence of BH4-Bcl-2 and BH4-Bcl-Xl are very similar. The cylindrical tube represents the predicted a-helical structure (PSIPREDv2.7). The
central modulatory domain of the IP3R1, containing the Bcl-2-binding site (a.a. 1389–1408), is depicted (Dom3¼ a.a. 923–1581). A peptide corresponding to a.a. 1389–1408
(IDP) could prevent binding of Bcl-2 to IP3Rs. (b) Unidirectional
45Ca2þ fluxes in permeabilized MEF cells plotted as 45Ca2þ content (counts per min (c.p.m.)) as a function of
time (min). Ca2þ release was activated by 3 mM IP3 (gray bar) in the absence or presence of the different BH4-domain peptides (black bar). A typical experiment is shown.
(c) Same experiment as in (b), but results are plotted as fractional loss (%/2 min) as a function of time. (d) IICR was quantified as the fractional loss after 2 min of IP3 incubation
minus the fractional loss before the IP3 addition. IICR in the presence of vehicle was set as 100% and other values were normalized to this value. A dose-response curve is
shown for BH4-Bcl-2, a non-binding mutant of BH4-Bcl-2 (BH4-Bcl-2BIND), BH4-Bcl-2 SCR and BH4-Bcl-Xl, obtained from three to four independent experiments. Data points
represent mean±S.E.M. (e) Intracellular Ca2þ signals in intact C6 glioma cells were monitored using Fluo-3. Cells were loaded with caged IP3 (50mM) and electroporated
with different BH4-domain peptides (20 mM) and/or IDP. IP3 was released by a UV flash and a rapid increase in cytosolic [Ca
2þ ] was observed. (f) Quantitative analysis of the
area under the curve in (e) was obtained from at least six independent experiments and data are plotted as mean±S.E.M. These data indicate that BH4-Bcl-2 significantly
inhibited IICR, whereas the other BH4-domain peptides did not. IDP (20 mM) prevented the inhibition of IICR by BH4-Bcl-2. (g) A typical experiment in Fluo-3-loaded C6 glioma
cells loaded with 20mM of different BH4-domain peptides or IDP depicting Ca2þ signals in response to ATP (1 mM). For clarity reasons, Ca2þ responses in cells loaded with
vehicle, BH4-Bcl-2, BH4-Bcl-2 þ IDP or BH4-Bcl-Xl are shown. (h) Quantitative analysis of the area under the curve of the ATP-induced Ca2þ signals in intact Fluo-3-loaded
C6 glioma cells loaded with the different BH4-domain peptides (20 mM) in response to 1mM ATP (5-9 independent experiments). (i) Similar experiment as (g) except that cells
were pretreated with EGTA (1 mM) 1 min before exposure to thapsigargin (TG; 2.5mM). (j) Quantitative analysis of the area under the curve of the TG-induced Ca2þ
responses (five independent experiments)
Different BH4-motif properties of Bcl-2 and Bcl-Xl
G Monaco et al
296
Cell Death and Differentiation
Different BH4-motif properties of Bcl-2 and Bcl-Xl
G Monaco et al
297
Cell Death and Differentiation
(Figure 1d and Supplementary Figure 1C). We repeated the
experiments using more physiological conditions, like 300 nM
free Ca2þ (Supplementary Figure 2B), 1mM free Ca2þ
(Supplementary Figure 2C) and 1mM Mg-ATP
(Supplementary Figure 2D), and found that 40mM BH4-Bcl-2
equally inhibited IICR.
Next, we examined the differential regulation of IP3Rs
by BH4-Bcl-2 and BH4-Bcl-Xl in C6 glioma cells, a
cellular model optimized for in situ electroporation of
membrane-impermeable molecules.32,33 We loaded
BH4-Bcl-2 or BH4-Bcl-Xl (both 20 mM) by electroporation
and found that BH4-Bcl-2 inhibited IICR triggered by
IP3 photoliberation from its caged precursor in intact C6
cells (50mM; Figures 1e and f), whereas BH4-Bcl-Xl did not.
BH4-Bcl-2SCR and BH4-Bcl-2BIND control peptides
did not reduce IICR. The inhibition by BH4-Bcl-2 was
completely prevented by loading the cells with IDP (20 mM),
indicating a competitive binding of BH4-Bcl-2 to IP3Rs. Similar
results were obtained using adenosine 50-triphosphate (ATP;
1mM), a physiological agonist provoking IP3R-mediated Ca
2þ
release in these cells (Figures 1g and h). Finally, we assessed
the TG (2.5 mM)-releasable Ca2þ in these cells 1min after
exposing the cells to EGTA (1mM) and found no differences
among the different conditions (Figures 1i and j). Hence, the
decreased ATP-induced Ca2þ release in the presence of
BH4-Bcl-2 was not because of decreased ER Ca2þ -store
content.
These results indicate that BH4-Bcl-2 and BH4-Bcl-Xl
differentially regulate IP3R function independently of the ER
Ca2þ -store content.
BH4-Bcl-2 and BH4-Bcl-Xl differentially bind to the
central domain of the IP3R. Next, we compared the
binding of BH4-Bcl-2 and BH4-Bcl-Xl with glutathione-S-
transferase (GST)-Dom3 (i.e. a.a. 923–1581 of IP3R1;
Figures 2a and b). Using GST pull-down assays, we found
that BH4-Bcl-2, but not BH4-Bcl-Xl, strongly and specifically
interacted with GST-Dom3. However, we consistently
noticed a higher nonspecific binding of BH4-Bcl-Xl to GST
than for BH4-Bcl-2. The reason for this is unclear. BH4-Bcl-
2BIND was not pulled down by GST-Dom3 (Figures 2a and b),
indicating that surface-accessible residues are important for
interaction with IP3Rs.
We also assessed the binding of GST-Dom3 to BH4-Bcl-2
and BH4-Bcl-Xl in a more quantitative manner using surface
plasmon resonance (SPR).Wemonitored the binding of GST-
Dom3 (Figures 3a–c) andGST (Supplementary Figures 3A–C
and Figure 3e) to the streptavidin-coated sensor chip contain-
ing immobilized biotinylated peptides. Background signals
obtained from the reference flow cell containing the scrambled
peptides were subtracted to generate response curves. In
each sensorgram, the association phase is plotted. GST (up
to 40 mM) bound to neither biotin-BH4-Bcl-2 nor biotin-BH4-
Bcl-Xl (Supplementary Figures 3A–C). GST-Dom3 displayed
a concentration-dependent increase in resonance units, in the
biotin-BH4-Bcl-2-containing flow cell (Figure 3a). This indi-
cates a specific binding toward biotin-BH4-Bcl-2 with esti-
mated dissociation constant (Kd) ofB1 mM (Figure 3c). In the
biotin-BH4-Bcl-Xl-containing flow cell (Figure 3b), GST-Dom3
resulted in significantly less increase in resonance units
(Figure 3c).
We also monitored the binding of GST-Dom3 to biotin-BH4-
Bcl-2BIND corrected for the response to the scrambled
counterpart (Figure 3d). Clearly, GST-Dom3 did not specifi-
cally bind to biotin-BH4-Bcl-2BIND. The negative values in the
sensorgrams indicate a slightly higher binding of GST-Dom3
to the scrambled version.
As the Bcl-2-binding site28 is largely conserved among the
different IP3R isoforms, we compared the BH4-Bcl-2-binding
properties of the GST-Dom3 (3.3 mM) derived from IP3R1,
IP3R2 and IP3R3 (Figures 3e and f). GST-Dom3 from all
three IP3R isoforms bound to biotin-BH4-Bcl-2 with roughly
similar potencies (Figures 3e and f). The quality of the purified
GST-fusion proteins was controlled using sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE;
Figure 3g).
Figure 2 A GST-fusion protein corresponding to the central, modulatory domain of IP3R1 binds BH4-Bcl-2, but not BH4-Bcl-Xl or BH4-Bcl-2BIND. (a) GST pull-down
assays were used for assessing the binding of BH4-Bcl-2, BH4-Bcl-Xl or BH4-Bcl-2 BIND to either GST or GST-Dom3. Samples were analyzed via SDS-PAGE and total
protein was stained. Bands corresponding to the BH4-domain peptides were quantified using ImageQuant. (b) The results of 3–7 independent experiments are plotted as
mean±S.E.M. **Significantly different from GST control (Po0.01)
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Identification of residues in BH4-Bcl-2 responsible for
inhibiting IP3Rs. Next, we investigated which residues in
BH4-Bcl-2 are responsible for interaction with IP3Rs. Based
on a bioinformatics approach,30 we successively changed
the various predicted surface-accessible residues into
alanines (Figure 4a) and investigated their properties
toward inhibiting IICR as described in Figure 1. We applied
60mM of the different BH4-Bcl-2 mutant peptides. This
concentration, when used for wild-type BH4-Bcl-2, reduced
the IICR to B20% of its control value (Figure 4b). This
analysis revealed that BH4-Bcl-2 acts as a discontinuous
binding domain, in which every surface-accessible residue
(Asp10, Arg12, Lys17, His20, Tyr21, Gln25, Arg26, Tyr28)
contributed to the inhibition of IICR. In particular, Lys17,
His20, Tyr21 or Arg26 seemed critical for the inhibitory
properties of BH4-Bcl-2. Moreover, changing these residues
into an Ala may indirectly affect the binding of BH4-Bcl-2 to
IP3Rs by altering its a-helical properties. It has to be noted
that although minor changes in the secondary structure can
occur, all Ala mutants displayed similar predicted a-helical
properties as the wild-type BH4-Bcl-2 using PSIPRED vs3.0
(Supplementary Figure 4, http://bioinf.cs.ucl.ac.uk/psipred/).
Sequence alignment identifies a difference of one
critical residue essential for differential IP3R-inhibitory
properties of BH4-Bcl-2 and BH4-Bcl-Xl. Sequence
alignment shows that Lys17 (K17) in BH4-Bcl-2
corresponds to Asp11 (D11) in BH4-Bcl-Xl (Figure 5a),
thereby introducing a charge change in the middle of the
a-helical structure.29,34,35 Hence, we made a mutant BH4-
Bcl-2 peptide in which we replaced Lys17 by an aspartate
(BH4-Bcl-2 K/D) and a mutant BH4-Bcl-Xl peptide in which
we replaced Asp11 by a lysine (BH4-Bcl-Xl D/K). Strikingly,
we found that BH4-Bcl-2 K/D failed to inhibit IICR, whereas
BH4-Bcl-Xl D/K strongly reduced IICR (Figures 5b and c).
Dose-response curves (Figure 5d) indicated that BH4-Bcl-2
and BH4-Bcl-Xl D/K inhibited IICR with an IC50 of 30 and
60 mM, respectively. In contrast, BH4-Bcl-Xl and BH4-Bcl-2
K/D were largely ineffective. The effects of the BH4-domain
mutants on IICR were also observed in intact C6 glioma cells
using caged IP3 (Figures 5e and f). In contrast to BH4-Bcl-2,
BH4-Bcl-2 K/D did not inhibit IICR in intact cells, whereas in
contrast to BH4-Bcl-Xl, BH4-Bcl-Xl D/K was able to
significantly reduce IICR. Similar results were obtained
using the physiological agonist ATP (1mM; Figure 5g),
whereas none of the BH4-domain peptides did alter the
amount of TG (2.5 mM)-releasable Ca2þ from the ER
(Figure 5h).
The importance of this critical residue was underpinned by
SPR experiments using immobilized biotin-BH4-Bcl-2 K/D
and biotin-BH4-Bcl-Xl D/K. Consistent with the functional
data, BH4-Bcl-2 K/D largely lost its ability to interact with
Figure 3 The central, modulatory domain of IP3R1 binds to immobilized biotin-BH4-Bcl-2, but not to biotin-BH4-Bcl-Xl, in SPR experiments. (a–c) Sensorgrams are
obtained after background correction for binding to the respective scrambled versions of the biotinylated BH4-domain peptides. The association phase is shown upon addition
of different concentrations of purified GST-Dom3 to biotin-BH4-Bcl-2 (a) or biotin-BH4-Bcl-Xl (b). A typical experiment is shown. (c) The quantitative analysis of the binding
properties of GST-Dom3 to either biotin-BH4-Bcl-2 or biotin-BH4-Bcl-Xl is shown. Values were obtained from three independent experiments and are plotted as
mean±S.E.M. (d) Sensorgrams representing the association phase of different concentrations of GST-Dom3 for the binding to either biotin-BH4-Bcl-2 or biotin-BH4-Bcl-
2BIND. All curves are background corrected for binding to the respective scrambled peptides. (e) Sensorgrams representing the binding of purified GST-Dom3 (3.3mM)
obtained from IP3R1, IP3R2 and IP3R3 to biotin-BH4-Bcl-2. GST (3.3mM) was included as a control. (f) Quantitative analysis of the binding of purified GST and GST-Dom3
obtained from IP3R1, IP3R2 and IP3R3 (all at 3.3mM) to biotin-BH4-Bcl-2. Values were obtained from three independent experiments and are plotted as mean±S.E.M. (g) A
representative GelCode Blue-stained 4–12% Bis-Tris NUPAGE gel run in MOPS-SDS buffer showing the quality of the purified GST and GST-Dom3 derived from IP3R1,
IP3R2 and IP3R3 used in these SPR experiments. The upper arrow indicates the full-length GST-IP3R-fusion proteins, whereas the lower arrow indicates parental GST
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GST-Dom3 (Figure 5i), whereas BH4-Bcl-Xl D/K was able to
bind GST-Dom3 (Figure 5j).
Taken together, these data indicate that one single residue
difference between BH4-Bcl-2 and BH4-Bcl-Xl can explain
their differential action on IP3Rs.
BH4-Bcl-2 and BH4-Bcl-Xl differentially affect
apoptosis. Next, we assessed whether BH4-Bcl-2 and
BH4-Bcl-Xl displayed a difference in protection against
apoptotic cell death in C6 glioma cells triggered by loading
the cells with cytochrome c (CytC; 10 mM, 25 min) or by
incubation with staurosporine (STS; 2 mM, 6 h). The apoptotic
index (AI) was determined and expressed relative to the
condition in which apoptosis was triggered in the absence of
BH4 peptides (vehicle), which was set to 100%.
We first examined whether CytC interaction with the IP3R
contributed to CytC-induced apoptosis in the C6 cell model.
The CytC–IP3R interaction is part of a positive feedback loop
that enhances cell death by promoting ER Ca2þ release
through IP3R channels.
36,37 We examined CytC-induced cell
death in the absence and presence of a peptide matching the
CytC-binding site on IP3Rs (IP3RCYT; 50 mM). Cells loaded
with IP3RCYT displayed a decrease of B50–60% in CytC-
induced cell death (Figure 6a). These results indicate that part
of the CytC-induced cell death was because of CytC binding to
the IP3Rs. We tested the different BH4-domain peptides
(20mM) in this cell system and found that both BH4-Bcl-2 and
BH4-Bcl-Xl protected against CytC-induced cell death.
However, BH4-Bcl-2 was significantly more potent in protect-
ing than BH4-Bcl-Xl (Figure 6b). The BH4-Bcl-2SCR control
did not protect at all. Importantly, changing Lys17 into Asp in
BH4-Bcl-2 (BH4-Bcl-2 K/D) reduced the level of protection,
thereby resembling BH4-Bcl-Xl. In contrast, changing Asp11
into Lys in BH4-Bcl-Xl (BH4-Bcl-Xl D/K) increased cell
survival, thereby resembling BH4-Bcl-2.
To assess whether the difference in potency between BH4-
Bcl-2 and BH4-Bcl-Xl is because of their differential action on
the IP3R, the BH4-domain peptides were loaded together with
IDP competing with the IP3R for binding of Bcl-2. IDP
completely abolished the protective action of BH4-Bcl-2, but
not that of BH4-Bcl-Xl (Figure 6c).
We also used STS, which acts upstream of the mitochon-
dria and CytC release and initiates apoptosis via ER Ca2þ -
release-dependent mechanisms.38,39 STS induced apoptosis
with a minor fraction of these cells displaying secondary
necrosis (Figure 6d). Primary necrosis was not observed,
as all propidium iodide (PI)-positive cells were also
characterized by activated caspases (cysteine-dependent
Figure 4 Determination of the residues in BH4-Bcl-2 critical for inhibiting IICR. (a) Zoomed picture of the BH4 domain of Bcl-2 showing its surface-accessible residues is
depicted. (b) The inhibitory properties of different BH4-Bcl-2 mutant versions (60 mM), in which the surface-accessible residues were altered into alanines, were monitored in
unidirectional 45Ca2þ -flux assays in permeabilized MEF cells. Four of the six single alanine mutations (K17A, H20A, Y21A and R26A) had the largest effect on the inhibitory
action of the wild-type (wt) BH4-Bcl-2 domain
Figure 5 BH4-Bcl-2 and BH4-Bcl-Xl differ in one critical amino acid, which determines their effect on the IP3R. (a) Aligned sequence of the BH4 domain of Bcl-2 and Bcl-Xl
with indication of the surface-accessible residues (in color) is shown. The critical residue Lys17 in BH4-Bcl-2 is not conserved in BH4-Bcl-Xl (depicted in blue). The sequences
of these BH4-domain peptides are indicated. (b) A typical experiment of a unidirectional 45Ca2þ -flux assay in permeabilized MEF cells, comparing the effect of BH4-Bcl-2,
BH4-Bcl-Xl, BH4-Bcl-2 K/D and BH4-Bcl-Xl D/K (80 mM of peptides). (c) The quantification of the effects of the different BH4-domain peptides (80 mM) on IICR was obtained
from three to four independent experiments. Data points represent mean±S.E.M. *BH4-Bcl-2 and BH4-Bcl-Xl D/K are statistically different from control. $ BH4-Bcl-2 K/D is
statistically different from BH4-Bcl-2. #BH4-Bcl-Xl D/K is statistically different from BH4-Bcl-Xl. (d) A dose-response curve for the different BH4-domain peptides was obtained
from three independent experiments. Values are plotted as mean±S.E.M. (e) Representative IP3R-mediated Ca
2þ traces in intact C6 glioma cells using caged IP3 and UV
photoliberation. (f) Quantitative analysis of the area under the curve, of the traces in (e), was obtained from at least six independent experiments and data are plotted as
mean±S.E.M. BH4-Bcl-2 and BH4-Bcl-Xl D/K significantly inhibited IICR, in contrast to BH4-Bcl-2 K/D and BH4-Bcl-Xl. *BH4-Bcl-2 and BH4-Bcl-Xl D/K are statistically
different from control. $BH4-Bcl-2 K/D is statistically different from BH4-Bcl-2. #BH4-Bcl-Xl D/K is statistically different from BH4-Bcl-Xl. (g) Similar experiment as in (e and f),
except that Ca2þ signals were elicited by ATP (1 mM). Area under the curve of different control cells was determined and set at 100%. (h) Similar experiment as in (e and f),
except that cells were pretreated for 1 min with EGTA (1 mM) and exposed to thapsigargin (TG, 2.5mM). Area under the curve for control was determined and set at 100%.
Statistically significant differences were considered at Po0.05 (single symbols), Po0.01 (double symbols) and Po0.001 (triple symbols). (i) Quantitative analysis of data
obtained from three independent SPR experiments, in which the binding of different concentrations of GST-Dom3 to immobilized biotin-BH4-Bcl-2 was compared with its
binding to immobilized biotin-BH4-Bcl-2 K/D. The maximal signal (resonance units) during the association phase was used in this analysis. (j) Quantitative analysis of data
obtained from SPR experiments, in which the binding of GST-Dom3 to biotin-BH4-Bcl-Xl was compared with its binding to biotin-BH4-Bcl-Xl D/K. The maximal signal
(resonance units) during the association phase was used in this analysis
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aspartate-specific proteases). Results with STS were similar to
those obtained with CytC loading (Figure 6e). Both BH4-Bcl-2
andBH4-Bcl-Xl, but not BH4-Bcl-2SCR, protected against STS-
induced cell death. However, BH4-Bcl-2 was significantly more
potent than BH4-Bcl-Xl. BH4-Bcl-2-mediated protection against
STS was completely suppressed by IDP, whereas the effect of
BH4-Bcl-Xl was independent of IDP.
As an additional control, we used first procaspase activating
compound (PAC-1; 150mM, 6h), a direct procaspase-3
activating compound downstream of CytC.40 These condi-
tions caused apoptosis in B15% of the cell population. We
found that BH4-Bcl-2 and BH4-Bcl-Xl did not protect against
PAC-1-induced cell death, confirming that the target of these
peptides is indeed upstream of caspase-3 (Figure 6f).
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Co-loading of BH4-Bcl-2 with BH4-Bcl-Xl in C6 glioma cells
did not display an additive effect toward their protection
against CytC- and STS-induced cell death (Figure 6g and
Supplementary Figure 5). The protective effects of both BH4-
Bcl-2 and BH4-Bcl-Xl against CytC-induced apoptosis were
ablated when the positive feedback loop of CytC on the IP3R
was prevented by co-loading IP3RCYT peptide (Figure 6h).
Collectively, these data indicate that the BH4 domains of
Bcl-2 and Bcl-Xl both protect against apoptosis by acting on
different targets upstream of caspase activation. Although the
protective effect of BH4-Bcl-2 was stronger and largely
dependent on its interaction with a specific binding site on
the IP3R, the protective effect of BH4-Bcl-Xl is independent of
binding to the IP3R. Nevertheless, in these paradigms
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BH4-Bcl-Xl likely acts on a target that functions downstreamof
the IP3R-signaling cascade.
Full-length Bcl-2 K/D is less efficient in binding IP3Rs,
inhibiting IP3R activity and protecting against Ca
2þ -
dependent apoptosis. Finally, we tested whether the
critical Lys17 identified in BH4-Bcl-2 plays a crucial role in
the IP3R-inhibitory action of full-length Bcl-2. Therefore, we
mutated Lys17 into Asp in full-length 3xFLAG-Bcl-2, creating
3xFLAG-Bcl-2 K/D.
First, we compared the GST-Dom3-binding properties of
3xFLAG-Bcl-2 and 3xFLAG-Bcl-2 K/D by expressing these
proteins in COS-1 cells and using GST pull-down assays
(Figure 7a). We found that the binding of 3xFLAG-Bcl-2 K/D to
GST-Dom3 was severely compromised compared with wild-
type 3xFLAG-Bcl-2 (Figure 7b).
Next, we examined the effect of 3xFLAG-Bcl-2 and
3xFLAG-Bcl-2 K/D overexpression in COS-1 cells on ATP-
induced Ca2þ release. We applied 1mM ATP, a submaximal
concentration for triggering Ca2þ signals, in Fura-2-loaded
COS-1 cells. We monitored the Ca2þ signals in mCherry-
transfected cells (Supplementary Figure 6). In each experi-
ment, 10 cells were selected and calibrated Ca2þ signals
were obtained. Typical Ca2þ responses in empty vector-,
3xFLAG-Bcl-2- and 3xFLAG-Bcl-2 K/D-transfected cells are
shown in Figures 7c–e, respectively. Cells expressing
3xFLAG-Bcl-2 displayed blunted ATP-triggered Ca2þ signals
in comparison with empty vector- or 3xFLAG-Bcl-2 K/D-
transfected cells (Figure 7f). 3xFLAG-Bcl-2 was much more
potent in inhibiting IP3R-mediated Ca
2þ signals than
3xFLAG-Bcl-2 K/D (Figure 7f). In addition, there was no
difference for TG-induced Ca2+ signals (Figure 7g). Finally,
we examined the effect of 3xFLAG-Bcl-2 and 3xFLAG-Bcl-2
K/D overexpression on the protection against STS-induced
apoptosis. We used the cleavage of poly-(ADP-ribose)-
polymerase (PARP), a downstream target of activated
caspase-3, to monitor STS-induced apoptosis in transfected
COS-1 cells (Figure 7h). Compared with control cells,
3xFLAG-Bcl-2 significantly reduced PARP cleavage upon
STS treatment. 3xFLAG-Bcl-2 K/D wasmuch less potent than
3xFLAG-Bcl-2 in preventing STS-induced PARP cleavage
(Figure 7i).
We confirmed these findings in WEHI7.2 cells, which
contain very low Bcl-2 levels. We created stable WEHI7.2
cell lines expressing either Bcl-2 or Bcl-2 K/D. First, western
blotting analysis revealed that both stable cell lines displayed
similar levels of Bcl-2 and Bcl-2 K/D (Figure 8a). Next, we
monitored apoptosis by western blotting analysis with PARP
antibodies (Figure 8b), annexin V-fluorescein isothiocyanate
(FITC)/PI fluorescence-activated cell sorting (FACS) analysis
(Figures 8c and d) and caspase-3-activity assay (Figure 8e).
In all assays, Bcl-2 overexpression protected WEHI7.2 cells
against STS-induced apoptosis, whereas Bcl-2 K/D was less
effective than wild-type Bcl-2. These data correlate well with
the IP3R-binding and Ca
2þ -signaling results obtained in
COS-1 cells. Hence, Lys17 seems an important residue in
the BH4 domain of full-length Bcl-2 for mediating Bcl-2-
dependent inhibition of IP3R-mediated Ca
2þ signals and
protection against STS-induced cell death.
Discussion
The major findings of this study are that (1) BH4-Bcl-2 and
BH4-Bcl-Xl, although very similar in primary sequence and
secondary structure,29,34,35 act differentially on IP3Rs, IICR
and Ca2þ -dependent apoptosis; (2) one critical residue that
has an opposite charge in BH4-Bcl-2 versus BH4-Bcl-Xl is
responsible for their distinct biological properties; and (3)
mutating this residue in the BH4 domain of full-length Bcl-2
decreases its ability to bind and inhibit IP3Rs and to protect
against apoptotic stimuli. We pinpointed one residue critical
for inhibiting IP3Rs in the sequence of BH4-Bcl-2 (Lys17) that
was not conserved in BH4-Bcl-Xl (Asp11). This residue is of
key importance for the specific action of BH4-Bcl-2 on the
IP3R. Changing Asp11 in BH4-Bcl-Xl into a Lys induced IP3R
binding and inhibition, leading to a BH4-Bcl-2-like function.
Bcl-2 and Bcl-Xl both act at the mitochondrial and the
ER membranes, where they regulate ER Ca2þ dynamics
via interaction with the IP3R.
20–23,26 Several reports
suggested that Bcl-2 predominantly inhibits proapoptotic
Ca2þ transients, whereas Bcl-Xl predominantly stimulates
Figure 6 BH4-Bcl-2, but not BH4-Bcl-Xl, protects against CytC- and STS-induced apoptosis via its interaction with the IP3R. (a–c) Loading of CytC (10 mM) in C6 glioma
cells provoked a dramatic increase in the number of caspase-positive cells and cells with a fragmented nucleus (both quantified 25 min later) compared with cells loaded with
buffer only ($ in (a) indicates that CytC significantly increases the apoptotic index compared with the control loading condition lacking CytC; the significance indication for CytC
versus control was omitted from the other panels for clarity reasons). All results were obtained from four to eight independent experiments and are plotted as mean±S.E.M.
Statistically significant differences are indicated as in Figure 5. (a) Co-loading of the IP3R peptide corresponding to the CytC-binding site (IP3RCYT 50mM) together with CytC
significantly (*) reduced the apoptotic index, indicating that CytC-induced apoptosis was amplified by its action on the IP3R. (b) BH4-Bcl-2, BH4-Bcl-2 K/D, BH4-Bcl-Xl and
BH4-Bcl-Xl D/K (20 mM) significantly (*) protected against CytC-induced apoptosis in both assays, but not BH4-Bcl-2SCR. However, BH4-Bcl-2 was significantly ($) more
potent than BH4-Bcl-Xl. Furthermore, Bcl-2 is significantly more potent than Bcl-2 K/D (þ ), whereas Bcl-Xl D/K is significantly more potent than BH4-Bcl-Xl (#). (c) BH4-Bcl-2-
mediated protection against CytC-induced apoptosis was alleviated by co-loading with 20 mM IDP, whereas the antiapoptotic activity of BH4-Bcl-Xl was not affected by IDP.
Thus, BH4-Bcl-2, BH4-Bcl-Xl and BH4-Bcl-Xlþ IDP significantly (*) reduced CytC-induced apoptosis, but not BH4-Bcl-2þ IDP. Furthermore, BH4-Bcl-2þ IDP is significantly
($) different from BH4-Bcl-2. (d) Characterization of the STS (2mM)-induced cell death profile by analyzing the percentage of cells staining positive for propidium iodide (PIþ ),
caspase activation (Caspase) and both PI and caspase activation (PIþ and Caspase) as a function of time. (e) Similar approach as in (c) but with STS as an apoptotic trigger
(applied in the medium for 6 h at 2 mM). (f) Similar approach as in (a–c), but with PAC-1, a small molecular activator of caspase-3, as an apoptotic trigger (applied in the
medium for 6 h at 150mM). (g) Effect of combining BH4-Bcl-2 and BH4-Bcl-Xl (both 20 mM) on CytC-induced apoptosis. *All conditions significantly reduced CytC-induced
apoptosis. $The combination of BH4-Bcl-2 and BH4-Bcl-Xl is significantly different from BH4-Bcl-Xl, but not from BH4-Bcl-2. These results indicate no additive effect by
combining BH4-Bcl-2 with BH4-Bcl-Xl. (h) Effect of BH4-Bcl-2 and BH4-Bcl-Xl on CytC-induced apoptosis in the presence of IP3RCYT peptide. *All conditions significantly
reduced CytC-induced apoptosis. However, the protective effects of both BH4-Bcl-2 and BH4-Bcl-Xl were ablated in the presence of IP3RCYT peptide (50mM) and thus did
not significantly differ from the vehicle-treated condition
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IP3R-mediated prosurvival Ca
2þ oscillations.21–23,26,28 Neverthe-
less, other reports showed that Bcl-2 too may enhance IP3R
activity20,25 and/or stimulate Ca2þ oscillations.21,41 Hence,
until now, it was not clear whether Bcl-2 and Bcl-Xl displayed
distinct functional properties toward regulating IP3Rs and thus
Ca2þ -regulated apoptosis or whether they were similar in
their action. As we recently showed that BH4-Bcl-2 was
sufficient to protect against IP3R-mediated apoptosis, we now
made a direct comparison of the BH4-domain properties of
Bcl-2 and Bcl-Xl by using synthetic peptides. Our study
reveals a specific cellular function for the BH4 domain of Bcl-2
as a potent inhibitor of IICR and Ca2þ -dependent apoptosis,
which is not shared by the BH4 domain of Bcl-Xl, although
both motifs are very similar in sequence and structure. Our
data indicate that this is because of a critical charge difference
in one of the surface-accessible amino-acid residues. As a
result, BH4-Bcl-Xl did not inhibit Ca2þ flux through the IP3R.
Nevertheless, BH4-Bcl-Xl protected against cell death.
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However, this effect was significantly smaller than for BH4-
Bcl-2 and was not due to inhibition of IICR. This was
concluded from the observation that IDP counteracting the
effect of BH4-Bcl-2 did not interfere with the protective
function of BH4-Bcl-Xl. Finally, using exogenous expression
in COS-1 andWEHI7.2 cells, we demonstrated that the role of
Lys17 is important for the action of full-length Bcl-2 on the
IP3R, as full-length Bcl-2 K/D was much less efficient in
binding and inhibiting IP3Rs as well as in protecting against
apoptotic stimuli. We observed a weak binding of full-length
Bcl-2 K/D (i.e.B20% of the binding of wild-type Bcl-2) to the
IP3R fragment, which indicates that residues other than
Lys17 may contribute to the binding of full-length Bcl-2
to the IP3R. This remaining binding of Bcl-2
K/D to IP3R may be responsible for the weak inhibitory
property of this protein on IP3R-mediated Ca
2þ signaling and
its protective effects against STS-induced apoptosis. How-
ever, the latter may also be related to the antiapoptotic actions
of Bcl-2 K/D through its hydrophobic cleft and may therefore
suggest that its ability to scaffold proapoptotic BH3-domain
proteins is unaffected by this mutation in the BH4 domain.
Clearly, whereas Bcl-2 exclusively interacts with the central
domain of the IP3R,
28 Bcl-Xl seems to interact with the
C-terminal tail of the IP3R.
23 The latter domain has been
proposed to contain two putative BH3-like domains and may
therefore interact with the hydrophobic cleft of Bcl-Xl.24
Besides the differential interaction with the IP3R, Bcl-2 and
Bcl-Xl could also differ with respect to other previously
identified targets of the BH4 domain of Bcl-2-family members,
as calcineurin, VDAC, RAF-1 (v-raf-1 murine leukemia viral
oncogene homolog 1), RAS (RAt Sarcoma), CED (cell death
abnormal)-4, paxillin and NF-kB (nuclear factor kappa-light-
chain enhancer of activated B cells), all of which may play a
role in apoptosis.30 A side-by-side comparison between Bcl-2
and Bcl-Xl will be required to examine whether there is a
distinct or preferential action of either domain on these targets
and whether the critical sequence difference between BH4-
Bcl-2 and BH4-Bcl-Xl revealed in this study affects their
activity or selectivity. Furthermore, considering the preferen-
tial targeting of Bcl-Xl to the mitochondrial outer membrane,42
we speculate that the protective action of BH4-Bcl-Xl may be
mediated by modulating mitochondrial targets.43 Although
BH4-Bcl-2 and BH4-Bcl-Xl appear to have distinct targets,
these targets likely do not function in completely independent
pathways. Indeed, a combination of BH4-Bcl-2 and BH-Bcl-Xl
did not provoke an additive protective effect and IP3RCYT
abolished the protective effect of both BH4-Bcl-2 and BH4-
Bcl-Xl against CytC-induced apoptosis. Thus, Bcl-Xl may act
through its BH4 domain on a target downstream of the IP3R,
whereas other targets independently of the IP3R/Ca
2þ -
signaling cascade cannot be excluded.
Our study may have important therapeutic consequences
for cancers dependent on high levels of Bcl-2, like chronic
lymphocytic leukemia.44,45 It may be possible to target the
BH4 domain of Bcl-2 in these malignancies, while preserving
essential biological functions of Bcl-Xl in other cells.
To conclude, our study is the first to reveal a difference in
the cellular activity of the BH4 domain of Bcl-2 and Bcl-Xl
toward IP3R regulation because of a single residue difference
between both domains.
Materials and Methods
Peptides. All synthetic peptides were obtained from Thermo Electron (Osterode,
Germany). Biotinylated peptides were obtained from Lifetein (South Pleinfield, NJ,
USA). Table 1 provides an overview of the different peptides used in this study and
their primary sequence.
Plasmid vector constructs. The pGEX-6p2 construct (Amersham
Biosciences, GE Healthcare, Diegem, Belgium) encoding a.a. 923–1581 of
mouse IP3R1 Domain 3 was obtained as previously described.
28 pcDNA3.1 (-)
mouse IP3R2 and rat IP3R3 were used as templates for the construction of
pGEX-6p2 vectors encoding the corresponding regions of IP3R2 (a.a. 913–1562)
and IP3R3 (a.a. 910–1427). Their respective coding regions were amplified by PCR
using the following primers: IP3R2 forward (5
0-GCGGCGGGATCCAATGTCAT
GAGGACCATCCACGG-30); IP3R2 reverse (50-GCGGCGGAATTCCTAGAGCGTGT
TGACCTGGCTG-30); IP3R3 forward (50-GCGGCGGGATCCAACGTGCGGAGGTC
CATCCAGGG-30); IP3R3 reverse (50-GCGGCGGAATTCTCACAGAGCGCTCATGTGG
GCATC-30). PCR products were purified, digested with BamHI and EcoRI (restrictions
sites are underlined above) and ligated into BamHI–EcoRI-treated pGEX-6p2 vector.
3xFLAG-Bcl-2 and -Bcl-Xl were generated by subcloning their respective full-length
cDNAs into p3xFLAG-myc-CMV-24 vector (Sigma-Aldrich, Munich, Germany) at HindIII/
BglII sites. The 3xFLAG-Bcl-2 K/D mutant was generated by PCR site-directed
mutagenesis introducing GAT (D) to replace AAG (K) in wild-type Bcl-2-donor DNA. The
following primers were used: 3F-Bcl-2 K/D forward (50-GATAACCGGGAGATAGT
GATGGATTACATCCATTATAAGCTGTCG-30); 3F-Bcl-2 K/D reverse (50-CGACAGCT
TATAATGGATGTAATCCATCACTATCTCCCGGTTATC-30).
The pSFFV-Neo and pSFFV-Neo-Bcl-2 vectors were kindly provided by
Professor Clark W Distelhorst. The pSFFV-Neo-Bcl-2 K/D vector was also obtained
by PCR site-directed mutagenesis. To introduce the desired point mutations, we
designed and used the following primers: Neo-Bcl-2 K/D forward (50-GACAAC
CGGGAGATAGTGATGGACTACATCCATTATAAGCTGTCG-30); Neo-Bcl-2 K/D
reverse (50-CGACAGCTTATAATGGATGTAGTCCATCACTATCTCCCGGTTGTC-30).
All constructs were verified by sequencing (Agowa AG, Berlin, Germany).
Figure 7 Mutating Lys17 into Asp in full-length Bcl-2 largely prevents the ability of Bcl-2 to bind to the IP3R, inhibit IP3R-mediated Ca
2þ release and protect against STS-
induced apoptosis in COS-1 cells. (a) Lysates from 3xFLAG-Bcl-2- and 3xFLAG-Bcl-2 K/D-overexpressing COS-1 cells were used in GST pull-down assays using purified
GST-Dom3. A representative western blot using anti-FLAG antibodies is shown. (b) Immunoreactive bands of at least five independent experiments were quantified using
ImageJ software. Values represent normalized values relative to their binding to GST. (c–e) COS-1 cells were co-transfected with mCherry plasmids and threefold excess of
either empty vector (c), 3xFLAG-Bcl-2 plasmid (d) or 3xFLAG-Bcl-2 K/D plasmid (e). Only cells expressing the mCherry plasmid were monitored as F340/F380. Fura-2 signals
were calibrated to obtain [Ca2þ ] (nM). Representative Ca2þ traces obtained from 10 Fura-2-loaded COS-1 cells in response to ATP (1mM) are shown. (f) Quantitative
analysis of the amplitude of the ATP-induced Ca2þ signals in mCherry-expressing COS-1 cells transfected with either empty vector, 3xFLAG-Bcl-2 plasmid or 3xFLAG-Bcl-2
K/D plasmid obtained from six independent experiments (mean±S.E.M.). *Both 3xFLAG-Bcl-2 and 3xFLAG-Bcl-2 K/D significantly reduce the peak [Ca2þ ] in response to
ATP. $3xFLAG-Bcl-2 K/D is significantly different from 3xFLAG-Bcl-2. (g) Quantitative analysis of the area under the curve of the TG-induced Ca2þ signal in these cells.
(h) Western-blot analysis using anti-PARP antibodies for monitoring PARP cleavage upon STS treatment (1 mM for 6 h) in 3xFLAG-vector, 3xFLAG-Bcl-2 and 3xFLAG-Bcl-2
K/D-expressing COS-1 cells. GAPDH was used as a loading control. (i) Quantification of the immunoreactive bands of the ratio of the cleaved over the full-length PARP in the
different transfected COS-1 cell populations from three independent experiments. The ratio of cleaved over full-length PARP obtained for control cells were set at 100% and
the other ratios were normalized to this value. Both 3xFLAG-Bcl-2 and 3xFLAG-Bcl-2 K/D significantly (*) prevent STS-induced apoptosis compared with the empty-vector
control, but 3xFLAG-Bcl-2 K/D is significantly ($) less potent than 3xFLAG-Bcl-2. Statistically significant differences are indicated as in Figure 5. We wish to remark that the
results obtained with 3xFLAG-Bcl-2 K/D were borderline significantly (*!) different from the empty-vector control (P¼ 0.051)
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Cell culture and transfections. MEF cells were cultured at 371C in a 9%
CO2 incubator in DMEM/Ham’s F12 medium (1 : 1; Invitrogen, Merelbeke, Belgium)
supplemented with 10% fetal calf serum (Sigma-Aldrich), 3.8 mM L-glutamine
(Glutamax, Invitrogen), 85 IU/ml penicillin and 85 mg/ml streptomycin (Invitrogen).
C6 glioma cells were cultured in DMEM/Ham’s F12 medium (1 : 1), containing 10%
fetal calf serum, 100 IU/ml penicillin, 100mg/ml streptomycin, 2.5mg/ml fungizone
and 2 mM L-glutamine at 371C, 5% CO2. COS-1 cells were seeded at a density of
15 000 cells/cm2 and cultured in DMEM supplemented with 10% fetal bovine serum
(Sigma-Aldrich) at 371C, 10% CO2. At 2 days after plating, COS-1 cells were
transiently transfected with the empty p3xFLAG-Myc-CMV-24 vector (Sigma-
Aldrich) or containing the cDNA of Bcl-2 or of the Bcl-2 K/D mutant. The transfection
procedure was performed using JetPRIME transfection reagent (Polyplus Transfections,
New York, NY, USA) and following the manufacturer’s recommendations.
For Ca2þ -imaging experiments, COS-1 cells were also co-transfected with a pcDNA
3.1-mCherry vector (Invitrogen) using a DNA ratio of 1 : 2 between pcDNA 3.1-mCherry
and p3xFLAG-Myc-CMV-24 vectors.
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Figure 8 Bcl-2 K/D is less effective than Bcl-2 in protecting against STS-induced apoptosis in stable WEHI7.2 cell lines. (a) Stable WEHI7.2 cell lines expressing Bcl-2 or
Bcl-2 K/D were created. The expression levels of Bcl-2 and Bcl-2 K/D were examined by western-blotting analysis using an anti-Bcl-2 antibody. Control WEHI7.2 cells display
very low endogenous Bcl-2 levels. (b) The cleavage of poly(ADP-ribose)-polymerase (PARP) in control WEHI7.2 cells, WEHI7.2 cells expressing Bcl-2 and WEHI7.2 cells
expressing Bcl-2 K/D was monitored by western-blotting analysis using an anti-PARP antibody. (c) FACS analysis of untreated and STS-treated PI/Annexin V-FITC-stained
control, Bcl-2-overexpressing and Bcl-2 K/D-overexpressing WEHI7.2 cell lines (10 000 cells per analysis). The apoptotic population was identified as the AnnexinV-FITC-
positive fraction (P2þ P3). The STS-induced apoptotic population was determined by the difference between the Annexin V-FITC-positive fraction of STS-treated cells and
the untreated cells: (P2þP3)STS–(P2þ P3)untreated. (d) Quantitative analysis from five independent experiments of the STS-induced apoptotic cell population, normalized to
the values obtained for the control WEHI7.2 cells (% of control). (e) Fluorimetric analysis from three independent experiments of the caspase-3 activity in untreated and
STS-treated control, Bcl-2-overexpressing and Bcl-2 K/D overexpressing WEHI7.2 cells using a plate-reader assay. The difference in relative fluorescence units between
STS-treated and untreated cells was calculated and plotted. In all these experiments, both Bcl-2 and Bcl-2 K/D significantly (*) protected against STS-induced apoptosis, but
Bcl-2 K/D was significantly ($) less potent than Bcl-2. Statistically significant differences are indicated as in Figure 5
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WEHI7.2 murine cells were grown as described previously28 and nucleofected
with either pSFFV-Neo, pSFFV-Neo-Bcl-2 or pSFFV-Neo-Bcl-2 K/D vectors, using
the Amaxa nucleofector and the dedicated Mouse T cell Nucleofector Kit according
to the manufacturer’s instructions (Amaxa-Lonza AG, Basel, Switzerland).
Subsequently, resistant cells were stably selected with 1 mg/ml G418 (Invitrogen)
as described in Chen et al.,21 but no clonal expansion was performed.
Western-blot analysis and antibodies. COS-1 and WEHI7.2 cells were
lyzed in a buffer containing 25 mM Hepes, pH 7.5, 1% Triton X-100, 10% glycerol,
0.3 M NaCl, 1.5 mM MgCl2, 1 mM DTT, 2 mM EDTA, 2 mM EGTA and protease
inhibitor cocktail tablets (Roche, Basel, Switzerland). The protein concentration of
samples was determined by Bradford assay (Sigma-Aldrich) using bovine serum
albumin (BSA) as standard. Proteins (10–20mg) were separated by NuPAGE 4–
12% Bis/Tris SDS-polyacrylamide gels using MES/SDS-running buffer (Invitrogen)
and transferred onto a polyvinylidene fluoride (PVDF) membrane. After blocking
with TBS containing 0.1% Tween and 5% non-fat dry milk powder, the membrane
was incubated with the primary antibody overnight. Next, membranes were
incubated for 1 h with a secondary horseradish peroxidase (HRP)-conjugated
antibody (dilution 1 : 2000 in 0.1% Tween/TBS). Protein detection was performed
with Pierce ECL Western Blotting Substrate (Thermo Fisher Scientific; p/a Perbio
Science BVBA, Erembodegem, Belgium). Bands quantification was done with
ImageJ software (rsbweb.nih.gov/ij/).
Primary antibodies used in this study are: mouse monoclonal ANTI-FLAG M2-
Peroxidase (HRP) (Sigma-Aldrich), rabbit polyclonal anti-PARP-1 (Alexis-Enzo Life
Sciences, Farmingdale, NY, USA), mouse monoclonal Anti-GAPDH clone GAPDH-
71.1 (Sigma-Aldrich) and mouse monoclonal anti-Bcl-2 (C2) (Santa Cruz
Biotechnology, Santa Cruz, CA, USA).
Unidirectional 45Ca2þ -flux assay. The 12-well clusters containing MEF
cells were fixed on a thermostated plate at 301C on a mechanical shaker. The
culture medium was aspirated, and the cells were permeabilized by incubating them
for 10 min in a solution containing 120 mM KCl, 30 mM imidazole-HCl (pH 6.8),
2 mM MgCl2, 1 mM ATP, 1 mM EGTA and 20mg/ml saponin. The non-mitochondrial
Ca2þ stores were then loaded for 45 min in 120 mM KCl, 30 mM imidazole-HCl
(pH 6.8), 5 mM MgCl2, 5 mM ATP, 0.44 mM EGTA, 10 mM NaN3 to prevent
mitochondrial Ca2þ uptake, and 150 nM free 45Ca2þ (28mCi/ml). After reaching
steady-state loading, cells were washed twice with 500ml of efflux medium (120 mM
KCl, 30 mM imidazole-HCl (pH 6.8), 1 mM EGTA) supplemented with 4mM
thapsigargin (Enzo Life Sciences, Farmingdale, NY, USA) to block SERCA
(sarcoplasmic-endoplasmic reticulum Ca2þ adenosine triphosphatase) Ca2þ -
uptake activity. Then, efflux medium was added and replaced every 2 min. IP3
(3mM) was added for 2 min after 10 min of efflux. At the end of the experiment, all
45Ca2þ remaining in the stores were released by incubation with 1 ml of a 2% (w/v)
SDS solution for 30 min. Ca2þ release was plotted as fractional loss (%/2 min) as a
function of time as previously described.46 The fractional loss represents the amount
of Ca2þ leaving the store in a 2-min time period divided by the total store Ca2þ
content at that time point. The effect of these BH4-domain peptides on IICR was
tested by preincubating the peptides 4 min before exposing the stores to IP3.
Electroporation loading. In situ electroporation of monolayer cell cultures
was performed as described before,32 according to a procedure that was optimized
for cell-death studies.33 C6 cells were grown to near confluency on 13 mm diameter
(apoptosis experiments) or 18 mm diameter (Fluo-3 Ca2þ imaging) glass
coverslips. Cell-monolayer cultures were washed three times with Hanks’
balanced salt solution buffered with Hepes (HBSS-Hepes) supplemented with
D-glucose (0.81 mM MgSO4, 0.95 mM CaCl2, 137 mM NaCl, 0.18 mM Na2HPO4,
5.36 mM KCl, 0.44 mM KH2PO4, 5.55 mM D-glucose, 25 mM Hepes, pH 7.4) and
subsequently three times with a low-conductivity electroporation buffer (4.02 mM
KH2PO4, 10.8 mM K2HPO4, 1.0 mM MgCl2, 300 mM sorbitol, 2.0 mM Hepes,
pH 7.4). They were placed 400 mm underneath a two-wire Pt-Ir electrode on the
microscopic stage and electroporated in the presence of a tiny amount of
electroporation solution (10 ml). Electroporation was done with 50 kHz bipolar pulses
applied as trains of 10 pulses of 2 ms duration each and repeated 15 times. The field
strength was 100 V peak-to-peak applied over a 500mm electrode separation
distance. After electroporation, cells were thoroughly washed with HBSS-Hepes.
Fluo-3 Ca2þ imaging. C6 cells were seeded on 18 mm diameter glass
coverslips and ester-loaded for 25 min with 5 mM Fluo-3-AM (Invitrogen) in HBSS-
Hepes supplemented with 1 mM of probenecid (Sigma-Aldrich) and 0.01% pluronic
F-127 (Invitrogen) at 371C, followed by de-esterification over 15 min. Subsequently,
cells were loaded with 100mM Dextran Texas Red (DTR; Invitrogen) and 20 mM
Bcl-2 peptides using the in situ electroporation technique as described above. For
UV flash-photolysis experiments, 50mM caged IP3 (Invitrogen) was also included in
the loading solution. Imaging was carried out using an inverted fluorescence
microscope equipped with a  40 oil-immersion objective and an intensified CCD
camera (Extended Isis camera, Photonic Science, East Sussex, UK).
In the case of stimulation by ATP, cells were superfused for 1 min with HBSS-
Hepes followed by 8 min with 1 mM of ATP (Sigma-Aldrich) in HBSS-Hepes,
whereas for TG experiments, cells were superfused for 1 min with Ca2þ -free
HBSS-Hepes containing 1 mM EGTA followed by 7 min with 2.5mM TG (Invitrogen)
in the same buffer. For IP3-photoliberation experiments, cells were, after 10 s, spot
illuminated with 1-kHz pulsed UV light (349 nm UV laser Explorer, Spectra-Physics,
Oxfordshire, UK) during 20 ms (20 pulses of 90 mJ energy measured at the entrance
of the microscope epifluorescence tube). The UV flash was applied at five different
places along the electroporated area per dish. Images (1/s) were generated with
software written in Microsoft Visual Cþ þ 6.0 (http://msdn.microsoft.com/en-us/
aa336402). Fluorescence-intensity changes in different cells (at least 20) were
analyzed with custom-developed FluoFrames software (generated by L Leybaert
Lab.). For UV flash photolysis experiments, fluorescence-intensity changes in all
cells in a predefined 3950mm2 region were analyzed. Ca2þ -concentration, (Ca2þ ),
changes were quantified as the area under the curve (AUC) of the separate Ca2þ
traces. N is equal to the number of dishes.
Preparation of GST-fusion proteins. BL21(DE3) Escherichia coli cells
were transformed with pGEX-6p2 constructs containing cDNAs of IP3R1 domain 3
(GST-Dom3 IP3R1: a.a. 923–1581), IP3R2 domain-3 analog (GST-Dom3 IP3R2:
a.a. 913–1562), IP3R3 domain-3 analog (GST-Dom3 IP3R3: a.a. 910–1427) or with
Table 1 Overview of the sequence of different peptides used in this study
Peptide name Peptide sequence
BH4-Bcl-2 RTGYDNREIVMKYIHYKLSQRGYEW
BH4-Bcl-Xl MSQSNRELVVDFLSYKLSQKGYSW
BH4-Bcl-2SCR WYEKQRSLHGIMYYVIEDRNTKGYR
BH4-Bcl-2BIND RTGYANAEIVMKYIAEKLSAAGKEW
BH4-Bcl-2 K/D RTGYDNREIVMKYIHYKLSQRGYEW
BH4-Bcl-Xl D/K MSQSNRELVVDFLSYKLSQKGYSW
IDP NVYTEIKCNSLLPLDDIVRV
Biotin-BH4-Bcl-2 Biotin-RTGYDNREIVMKYIHYKLSQRGYEW
Biotin-BH4-Bcl-Xl Biotin-MSQSNRELVVDFLSYKLSQKGYSW
Biotin-BH4-Bcl-2SCR Biotin-WYEKQRSLHGIMYYVIEDRNTKGYR
Biotin-BH4-Bcl-XlSCR Biotin-WYSKQRSLSGLVMYVLEDKNSQFS
Biotin-BH4-Bcl-2BIND Biotin-RTGYANAEIVMKYIAEKLSAAGKEW
Biotin-BH4-Bcl-2BINDSCR Biotin-WKEKAASLAGIMEYVIEAANTKGYR
Biotin-BH4-Bcl-2 K/D Biotin-RTGYDNREIVMDYIHYKLSQRGYEW
Biotin-BH4-Bcl-Xl D/K Biotin-MSQSNRELVVKFLSYKLSQKGYSW
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the empty vector. The expressed proteins were purified as previously described.28
All fusion proteins were affinity purified and dialyzed against standard phosphate-
buffered saline (PBS) without added Ca2þ or Mg2þ (2.67 mM KCl, 1.47 mM
KH2PO4, 137.93 mM NaCl, 8.06 mM Na2HPO4; Invitrogen) using Slide-A-Lyzer with
a cutoff of 3 kDa (Thermo Fisher Scientific, Pittsburg, PA, USA). After dialysis, the
concentration of the purified GST-fusion proteins was determined using BCA
Protein Assay Reagent (Thermo Fisher Scientific), and the quality and integrity were
examined by SDS-PAGE and GelCode blue stain reagent (Thermo Fisher
Scientific) before GST pull-downs or SPR analysis.
GST pull-downs. Equal amounts (30 mg) of the intact full-length GST-fusion
proteins or parental GST (control) were incubated in Interaction Buffer (50 mM
Tris-HCl, 300 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 0.5%
BSA and protease inhibitor cocktail, pH 7.0) with 30mg of different BH4 domains
(BH4-Bcl-2, BH4-Bcl-Xl or a non-binding mutant (BH4-Bcl-2BIND)) and immobilized on
glutathione-Sepharose 4B beads (GE Healthcare Europe GmbH, Munich, Germany)
via rotation in a head-over-head rotator for 2 h at 41C. The beads were washed four
times with modified Interaction Buffer (150 mM NaCl instead of 300 mM NaCl, without
BSA) and complexed GST-fusion proteins were eluted by incubating the beads with
40ml LDS (Invitrogen) for 3 min at 951C and collected after centrifuging at 500 g for
5 min. Eluates (10ml) were subjected to western-blot analysis and the total protein
content was visualized by GelCode blue staining of the gel.
For the pull-downs with full-length Bcl-2 proteins, 200mg of cleared lysate from
COS-1 cells transiently transfected with the 3xFLAG-Bcl-2 vector, 3xFLAG-Bcl-2-K/
D or the empty vector were incubated with GST-tagged proteins using the same
protocol as above. Eluates (10 ml) were subjected to western-blot and incubated
with anti-FLAG HRP-conjugated antibody, diluted 1 : 4000 in 0.1% Tween/TBS.
SPR measurements. SPR experiments were performed as described
before.47 The binding of GST-Dom3 and parental GST (control) to the wild-type
or mutated BH4 domain of Bcl-2 or Bcl-Xl was analyzed by SPR at 251C using a
Biacore 2000 instrument (Uppsala, Sweden). Equal amounts (200 ng or 58.2 pmol)
of 480% pure biotinylated BH4 peptides were immobilized on four different flow
cells of a streptavidin-coated sensor chip (BR-1000-32; Biacore, Uppsala, Sweden)
using PBS supplemented with 0.005% P20 (Polysorbate-20) at pH 7.0. At least
three independent sensor chips were used for the quantitative analysis.
Measurements with GST-fusion proteins as analyte were performed in PBS at a
flow rate of 30ml/min. Different concentrations of the analyte (injection volume
120ml) were used in a random order to assess binding, expressed in terms of
resonance units (RU). Bound peptide was removed by injection of 5 ml regeneration
buffer (25 mM NaOH, 0.002% SDS) at 10 ml/min. Background signals were obtained
from the reference flow cell, containing the BH4-scrambled peptide, and were
subtracted to generate response curves using Biaevaluation 3.0 software (Biacore,
http://www.biacore.com). In the analysis, only the association phase of the binding
curve was taken into account. Data from two to three different sensorgrams for each
condition were fitted by nonlinear regression analysis to a Hill–Langmuir binding
isotherm using Origin 7.0 (OriginLab Corporation, Northampton, MA, USA)
software.
Fura-2 Ca2þ imaging. At 2 days after co-transfection (mCherry þ 3xFlag
construct), COS-1 cells were loaded with Fura-2-AM (5 mM; Biotium, Inc., Hayward,
CA, USA) in modified Krebs buffer (135 mM NaCl, 5.9 mM KCl, 1.2 mM MgCl2,
11.6 mM Hepes, pH 7.3, 11.5 mM glucose and 1.5 mM Ca2þ ) for 30 min, followed
by de-esterification for 30 min. To buffer all free extracellular Ca2þ , 5 mM BAPTA
(Invitrogen) was added before each measurement. ATP (1 mM) or TG (5 mM)-
induced [Ca2þ ] rises were measured ratiometrically (excitation at 340 nm/380 nm,
emission detection at 510 nm) using Zeiss Axio Observer Z1 Inverted Microscope
equipped with a  20 air objective and an high-speed digital camera (Axiocam
Hsm, Zeiss, Jena, Germany). Intracellular cytoplasmic Ca2þ concentrations
([Ca2þ ]cyt) were calculated from the equation: [Ca
2þ ]cyt (nM)¼ KdQ
(R–Rmin)/(Rmax–R), where Kd is the dissociation constant of Fura-2 for Ca
2þ at
room temperature (220 nM), Q is the fluorescence ratio of the emission intensity
excited by 380 nm in the absence of Ca2þ to that in the presence of saturating
Ca2þ , R is the fluorescence ratio, Rmin and Rmax are the minimal and maximal
fluorescence ratios, respectively. The Rmin was measured by perfusion with 50 mM
EGTA in Ca2þ -free Krebs solution and Rmax was obtained by perfusion with 5 mM
ionomycin and 250 mM CaCl2. Only mCherry fluorescent (excitation 546 nm,
emission 610 nm) and Fura-2 loaded cells were considered for data analysis. Per
experiment, 10–15 cells were analyzed for a total of B80 cells per transfection
condition on 3 different experimental days. Traces were normalized to baseline
levels with Excel software (Microsoft Office) and for each experiment the average
peak value (D[Ca2þ ]cyt) was determined.
Apoptosis induction. For CytC-induced-apoptosis experiments, C6 cells
were loaded by in situ electroporation in the presence of 100mM DTR to identify the
loaded zone, 20mM of Bcl-2 peptides or 50mM IP3RCYT peptide and 10mM of
CytC (Sigma). After electroporation, cells were kept in 200ml culture medium for
25 min. For STS- and PAC-1-induced apoptosis experiments, cells were
electroporated in the presence of 100mM DTR and 20mM Bcl-2 peptides. After
electroporation, cells were kept in 200ml culture medium containing 2 mM STS
(Sigma-Aldrich) or 150mM PAC-1 (Tocris Bioscience, Ellisville, MO, USA) for 6 h.
For STS-induced apoptosis, COS-1 cells transiently transfected with 3xFLAG-
vectors and WEHI7.2 cells, and stably transfected with the various pSFFV-Neo
vectors, were treated for 6 h with 1 mM STS (Sigma-Aldrich).
Detection of apoptosis by fluorescence microscopy. Glioma cells
were stained first with 10mM of the CaspACE FITC-VAD-FMK ‘In situ Marker’
(Promega Benelux, Leiden, The Netherlands) in HBSS-Hepes for 40 min at 371C.
After fixing the cells with 4% paraformaldehyde (PFA) for 25 min at room
temperature, nuclei were additionally stained for 5 min with 1 mg/ml DAPI (Sigma) in
PBS supplemented with Ca2þ and Mg2þ (PBSDþ ). Cells were mounted with
Vectashield fluorescent mounting medium (VWR International, Leuven, Belgium) on
glass slides.
Five images (in each culture) were taken in the electroporated area using a Nikon
TE300 epifluorescence microscope equipped with a  10 objective (Plan APO, NA
0.45; Nikon) and a Nikon DS-5M camera (Nikon, Brussels, Belgium). The number of
caspase-positive cells and DNA-fragmented nuclei were counted in each image and
expressed relative to the number of nuclei present and stated as the AI. Small
groups of apoptotic bodies were counted as remnants of a single apoptotic cell.
Analyses were carried out blinded, making use of custom-developed counting
software. For the STS- and PAC-1-treated cultures, five additional images were
taken outside the electroporated area. The AI in the electroporated area was
expressed relative to the AI outside the area.
FACS analysis and microplate-based apoptosis assay. WEHI7.2
cells were pelleted by centrifugation and incubated with Annexin-V-FITC (Becton
Dickinson, USA) and PI (Invitrogen). Single-cell suspensions were analyzed by
FACSCanto (Becton Dickinson, Franklin Lakes, NJ, USA). Cell death by apoptosis
and secondary necrosis was scored by quantifying the population of Annexin-V-
FITC-positive cells and Annexin-V-FITC/PI-positive cells. Flow-cytometric data were
plotted and analyzed using BD FACSDiva Software (Becton Dickinson). Results
were normalized as percentage decrease over control conditions.
Caspase-3 activity of STS-treated-WEHI7.2 cells was measured according to the
protocol of the commercially available NucView 488 Caspase-3 Kit for live Cells
(Biotium). Cells were transferred to a 96-well plate at a density of 400 000 cells/well
and fluorescence was monitored using a FlexStation 3 microplate reader (Molecular
Devices, Sunnyvale, CA, USA). The fluorescence intensity units collected from
treated cells were normalized to untreated controls and plotted as changes in
relative fluorescence units (DRFU).
Data and statistical analysis. Data are expressed as mean±S.E.M.,
unless a typical experiment is shown (mean±S.D.). Statistically significant
differences were considered at Po0.05 (single symbols), Po0.01 (double
symbols) and Po0.001 (triple symbols) after using a two-tailed paired Student’s
t-test (Excel Microsoft Office) or one-way ANOVA and a Bonferroni post-test using
Origin 7.0.
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